FindTrial
Sign In

Research on the Application of Treatment Strategies Based on "Wu's Classification" for Solitary Hepatocellular Carcinoma in the Left Liver: A Multicenter, Prospective, Double-Blind, Randomized Controlled Study

Research on the Application of Treatment Strategies Based on "Wu's Classification" for Solitary Hepatocellular Carcinoma in the Left Liver: A Multicenter, Prospective, Double-Blind, Randomized Controlled Study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113302
Enrollment
Unknown
Registered
2025-11-27
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

"Wu's Classification" group:Type Ib employs laparoscopic anatomical resection of liver segment S2 or S3, Type II utilizes laparoscopic anatomical resection of liver segment S4, and Type IIIb involves
Control group:Traditional treatment methods

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age: 18–75 years; 2. Patients with a single tumour located in the left hepatic lobe classified as type Ib, II, or IIIb according to the Wu classification; 3. Patients with clinically confirmed hepatocellular carcinoma (HCC); 4. Preoperative Child-Pugh liver function grade A or B; 5. Absence of contraindications for laparoscopic liver resection; 6. ECOG Performance Status score of 0–1; 7. Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients classified as non-Ib, II, or IIIb according to the Wu classification; 2. Multiple tumours; 3. Postoperative pathological diagnosis of non-hepatocellular carcinoma (HCC); 4. Impaired hepatic reserve function (ICG R15 >=20%); 5. Severe cardiac or pulmonary disease rendering the patient unable to tolerate general anaesthesia; 6. Extrahepatic combined resection; 7. Concurrent tumours in sites other than the liver; 8. Patients with a history of prior liver resection, local ablation, transarterial chemoembolisation, or systemic therapy.

Design outcomes

Primary

MeasureTime frame
Overall survival time;Surgical blood loss;Conversion;Liver parenchyma transection time;Tumor margin;Postoperative complications;Postoperative liver function status;Postoperative intestinal function recovery time;Postoperative hospital stay;Reoperation situation;Readmission situation;Postoperative mortality;Postoperative pain assessment;Time without disease recurrence;Distant metastasis-free survival time;—

Secondary

MeasureTime frame
Operation time;—

Countries

China

Contacts

Public ContactFengwei Gao

West China Hospital of Sichuan University

gaofengwei@scu.edu.cn+86 189 9060 9527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026